NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conference:
Cantor Global Healthcare Conference at 9:30 a.m. ET on Friday, October 4, 2019.
Webcast information for this event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An archived webcast will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
For more information about Intercept, please contact:
Media inquiries: firstname.lastname@example.org